[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Significant equity grants: 12,275 RSUs and a 39,363-share option, providing long-term incentive alignment
• Clear vesting schedules: RSUs vest 25% annually over four years and the option vests over multi-year schedule through 2035
• Grants documented as direct ownership, simplifying ownership tracing

Negative

• Reported share disposals: 2,920 shares sold at $33.49 and 900 shares sold at $34.28, reducing direct holdings on specific lines
• Option exercise price of $33.49 may be near recent sale prices, indicating limited immediate intrinsic value if market price declined below that level (based solely on filing prices)

Insights

Securities Analyst

TL;DR: CFO received compensation in the form of RSUs and an option while executing small share disposals at ~$33–$34 per share.

The Form 4 documents routine equity compensation and limited open-market sales by the reporting CFO. Key items are a 39,363-share option exercisable at $33.49 and 12,275 RSUs granted with multi-year vesting schedules. The sales (2,920 shares at $33.49 and 900 shares at $34.28) reduced direct holdings reported on specific lines. Vesting schedules span four years for RSUs and standard multi-year vesting for the option, indicating retention-linked compensation rather than immediate liquidity events. No changes to derivative ownership counts beyond the documented grants are indicated.

Corporate Governance Expert

TL;DR: Transactions reflect standard executive compensation grants with documented vesting; limited sales were reported contemporaneously.

The disclosure provides clear grant terms: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly thereafter through 2035. These are typical structures to align executive incentives with long-term shareholder value. The filing also reports contemporaneous sales at market prices which are recorded separately. All reported holdings are direct. The form is properly executed by an attorney-in-fact, consistent with procedural norms for insiders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/01/2025		M		1,592	A	(1)	28,601	D
Class A Ordinary Share	09/01/2025		M		1,750	A	(1)	30,351	D
Class A Ordinary Share	09/01/2025		M		2,694	A	(1)	33,045	D
Class A Ordinary Share	09/01/2025		F		2,920	D	$33.49	30,125	D
Class A Ordinary Share	09/02/2025		M		1,861	A	(1)	31,986	D
Class A Ordinary Share	09/02/2025		F		900	D	$34.28	31,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	09/01/2025		A		12,275		(2)	(2)	Class A Ordinary Share	12,275	$0	12,275	D
Share Option	$33.49	09/01/2025		A		39,363		(3)	08/31/2035	Class A Ordinary Share	39,363	$0	39,363	D
Restricted Share Unit	(1)	09/01/2025		M			1,592	(4)	(4)	Class A Ordinary Share	1,592	$0	4,773	D
Restricted Share Unit	(1)	09/01/2025		M			1,750	(5)	(5)	Class A Ordinary Share	1,750	$0	3,500	D
Restricted Share Unit	(1)	09/01/2025		M			2,694	(6)	(6)	Class A Ordinary Share	2,694	$0	2,694	D
Restricted Share Unit	(1)	09/02/2025		M			1,861	(7)	(7)	Class A Ordinary Share	1,861	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.

3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.

5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

	/s/ Aaron Young, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity transactions did KNSA CFO Mark Ragosa report on Form 4?

The filing reports grants of 12,275 RSUs, a 39,363-share option with a $33.49 exercise price, additional RSU grants and sales of 2,920 shares at $33.49 and 900 shares at $34.28 on September 1-2, 2025.

What are the vesting terms for the RSUs and option reported by the KNSA CFO?

RSUs generally vest over four years with 25% vesting each year. The option vests 25% after one year then monthly in equal installments thereafter with a stated expiration date in 2035.

Did the Form 4 indicate whether holdings are direct or indirect for Mark Ragosa?

Yes. The filing reports ownership as Direct (D) for the listed RSUs, option and share holdings.

Were any shares sold by the reporting person in this filing?

Yes. The filing discloses sales of 2,920 Class A Ordinary Shares at $33.49 and 900 Class A Ordinary Shares at $34.28.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by /s/ Aaron Young, Attorney-in-Fact on behalf of the reporting person and dated 09/03/2025.